Back to search

National and Kapodistrian University of Athens

Αναστολή της ενεργοποιημένης κινάσης της τυροσίνης JAK2 λόγω της σημειακής μετάλλαξης V617F στα χρόνια μυελοϋπερπλαστικά σύνδρομα

Abstract

dc:description

Chronic Myeloproliferative Disorders CMPDs, which were first reported by Dameshek in 1951, are clonal hematopoietic stem cell disorders characterized by proliferation of 1 or more myeloid cell lineages in the bone marrow and increased numbers of mature or immature cells in peripheral blood. According to the Word Health Organization, CMPDs or Myeloproliferative Neoplasms MPNs, include Polycythemia Vera (PV), Essential Thrombocythemia (ET), Idiopathic Myelofibrosis (IMF), plus rarer subtypes such us chronic neutrophilic leukaemia (CNL), hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL). The identification in 2005 of the V617F mutation in the JAK2 gene in Chronic Myeloproliferative Disorders (CMPDs) or Myeloproliferative Neoplasms (MPNs ) may explain several characteristics of these diseases and provide a prognostic marker in clinical practice. The JAK2V617F mutation is present in 90% of Polycythemia Vera, PV, patients and in about a half of Essential Thrombocythemia, ET, and Idiopathic Myelofibrosis, IMF, patients respectively. The first purpose of this study was the investigation of the V617F mutation of the JAK2 gene in our patients and the correlation between the clinical phenotype of patients with the JAK2V617F mutation and without. Also, is important to evaluate the mutation load of the V617F mutated alleles in all patients and to find the correlation between the mutation load and the clinical phenotype of the patients. Secondly, we evaluate the mutation load of the V617F mutated alleles in PV patients after a treatment with the pegylated forms of INFa-2a. The second purpose of this study was the investigation of the mutations of the exon 12 of the JAK2 gene in the negative cases for the V617 mutation in PV. The third purpose of this study was the investigation of the mutations in the thrombopoietin receptor-MPL in the negative cases for the V617 mutation in ET and IMF samples. Patients were found to carry the V617F mutation in the exon 14 of the JAK2 gene and the other patients were negative. The proportion of positive cases per disease sutype was PV 434/480 (90.5%), IMF 9/18 (50%) and ET 525/880 (60%). The negative patients for the V617F mutation was PV 46/480 (9.5%), ET 355/880 (40%) and IMF 9/18 (50%) were searched for the exon 12 mutation of the JAK2 gene (N542-E543del, K539L, F537-K539delInsL, H538QK539L) and for mutation in the thrombopoietin receptor (MPLW515L/W515K). These mutations were detected using the allele-specific real-time polymerase chain reaction (AS-PCR) assay described by (Scott et al, 2007). The conclusions of our study: • Investigation of the JAK2V617F mutation in patients with PV, IMF, and ET. Correlations between the clinical phenotype of patients with or without the mutation. We observed that the clinical phenotype of the PV patients carried the JAK2V617F mutation had a increased level of WBC, PLT count and Hct level, but not in the level of the Hb. In the IMF patients we did not observed any differences. In the ET patients we observed that the level of the Hb, WBC and PLT count was increased. • Investigation of the mutation load of the V617F mutated alleles in patients with PV, IMF, and ET. Correlations between the mutation load of the V617F mutated alleles and the clinical phenotype of the patients. We observed an increased level of mutated alleles, more than 50% in PV patients. Instead the level of the mutated alleles in ET patients were lower (less than 50%). Also the level of the mutated alleles in IMF patients were highest from the ET and PV patients. We observed in PV patients correlation between the mutation load and the level of the Hb, Hct and WBC count and in ET patients between the mutation load and the level of the Plt count. • The conclusion, of the purpose of this study, has been carried out in 5 PV patients treated with the pegylated forms of the IFN-a-2a. The reduction of the mutation load started during the first year and it became undetectable after the 24 months of treatment a trend reported in (Kiladjian et al, 2008). Interestingly, of the previous report one of the responders had an increase of the mutation load during the treatment 19 with peg-IFNa-2a, and after a continuous therapy was able to achieve a molecular response. This observation is in agreement with the report of (Kiladjian et al, 2008) that a prolonged treatment with the peg-IFNa-2a would lead to an increase reduction of the mutation load of the JAK2V617 mutation. The complete and a partial molecular response was obtained of 4/5 patients with a rate of 80%. In this subset of patients the complete molecular remission was followed by a complete hematologic remission. Interestingly, of previous report, one of the five patients was unable to achieve a molecular response followed by a non hematologic reduction (Kiladjian et al, 2008). Similarly, of the recent report, one patient was able to maintain the molecular response for at least 6 months after the last treatment with peg-IFNa-2a (Larsen et al, 2008).The hematologic response was rapidly achieved in contrast to the molecular response. The hematologic response started after 6 months of treatment. A major complete response with a reduction in of all the blood parameters was achieved at least 12 months from the start point of the therapy. The complete molecular response rate was 80% for the group of PV patients. One of the responders was able to maintain the hematologic response for at least 6 months after the last treatment with peg-IFNa-2a. In conclusion, a prolonged therapy with peg-IFNa-2a administrated in a standard dose, provide in PV patients a reduction of the mutation load of the JAK2V617F mutation and in some cases the complete disappearance of the mutated alleles. This observation maybe is a tool of monitor the treatment efficacy of PV patients. • The conclusion, of the second purpose of this study has been carried out in 46 PV patients negative for the V617F mutation. The proportion of positive cases for the mutations of the exon 12 (N542-E543del, K539L, H538QK539L, F537-K539delInsL) were 3/46(6,5%), 1/46 (2,1), 1/46(2,1),none respectively. These patients was characterized by high level of Hct and Hb, mild leukocytosis and normal level of Platelet count. Correlation between positive cases for the mutations of the exon 12 and positive cases for the mutation of the JAK2V617F has show differences in the clinical phenotype. Specifically, differences were observed in the WBC count and the level of the Hct and Hb, but not in the PLT count. • The conclusion, of the third purpose of this study has been carried out in 364 patients, ET 355/364 (97%) and IMF 9/364 (3%) negative for the V617F mutation. The proportion of positive cases for the mutations in the thrombopoietin receptor (MPLW515L/W515K) were ET 23/355 (6.3%) and IMF 1/9 (0.2%). The MPLW515L mutation was found in 20 samples (5.4%) and the MPLW515K in 4 samples (1.09%). These patients was characterized by high level of the platelet count, normal level of the Hct and Hb and mild leukocytosis. Correlation between positive cases for the mutation MPLW515L and W515K has show that the patients carrying the MPLW515L mutation have a clinical phenotype characterized by an increased level of Hct and lower level of WBC count. The level of the PLT count was the same in these two groups of patients. Correlation between positive cases for the mutations of the thrombopoietin receptor and positive cases for the mutation of the JAK2V617F has show that the level of PLT, WBC and Hct were lower.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Palliou, Andrianna
  • Πάλλιου, Ανδριάννα

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27415

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Palliou, Andrianna; Πάλλιου, Ανδριάννα. Αναστολή της ενεργοποιημένης κινάσης της τυροσίνης JAK2 λόγω της σημειακής μετάλλαξης V617F στα χρόνια μυελοϋπερπλαστικά σύνδρομα. National and Kapodistrian University of Athens, 2011. http://hdl.handle.net/10442/hedi/27415